Soluble Therapeutics, a protein solubility company spun off from research at the University of Alabama at Birmingham, has acquired Seattle-based Dilyx Biotechnologies in a deal that will strengthen the ability of the company's flagship HSC technology.
“Researchers are constantly challenged with solubility and stability issues in the development of protein-based products,” said Dr. Joseph N. Garner, CEO of Soluble Therapeutics. “Our company understands the need to quickly resolve such issues during the development of both biologics and other protein-based products.
Help employers find you! Check out all the jobs and post your resume..
“Researchers are constantly challenged with solubility and stability issues in the development of protein-based products,” said Dr. Joseph N. Garner, CEO of Soluble Therapeutics. “Our company understands the need to quickly resolve such issues during the development of both biologics and other protein-based products.
Help employers find you! Check out all the jobs and post your resume..
